Finance · Crypto
AGM Group and HashBeaver Jointly Develop Desktop DePIN Node for Bitcoin Mining
AGM Group and HashBeaver Jointly Develop Desktop DePIN Node for Bitcoin Mining.
Sep 8 · 11:50GlobeNewswire
26,729 press releases indexed under finance.
AGM Group and HashBeaver Jointly Develop Desktop DePIN Node for Bitcoin Mining.
Seasoned financial services executive brings deep consumer lending and public markets expertise to advance Oportun’s mission and profitable growth. Seasoned financial services executive brings deep consumer lending and public markets expertise to advance Oportun’s mission and profitable growth.
Revenue cycle leaders identify three opportunities to improve healthcare cash flow by preventing revenue leakage, protecting earned revenue and prioritizing recovery. MILWAUKEE, Sept. 8, 2026 /PRNewswire/ -- As healthcare organizations face continued pressure on margins, staffing and cash...
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / KIDZ AI Inc. (NASDAQ:KIDZ)(NASDAQ:KIDZW) ("KIDZ AI" or the "Company"), an education technology company advancing AI infrastructure and GPU compute initiatives alongside its core EdTech operations, today announced the appointment of Karan Bansal as AI Security Advisor to support the Company's AI infrastructure initiatives. The appointment marks a further step in KIDZ AI's strategy of building out an enterprise AI compute platform. Karan Bansal has spent a decade in security engineering and was a founding engineer at AvidSecure, a cloud security company acquired by Sophos. He is an active contributor ..
KIDZ AI (NASDAQ: KIDZ) appoints Karan Bansal, founding engineer of Sophos-acquired AvidSecure, as AI Security Advisor to advance its AI infrastructure strategy.
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief...
Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that the Yale University’s IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND‑100.
70:30 joint venture with Integral Cleaning introduces drone and AI-enabled facade inspection to Singapore's commercial real estate sector, enhancing safety and operational efficiency. SINGAPORE, Sept. 8, 2026 /PRNewswire/ -- YYForce Inc. (NASDAQ: YFOR) ("YYForce" or the "Company"), an...
HOUSTON, Sept. 8, 2026 /PRNewswire/ -- Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), a Fortune 250 automotive retailer with 249 dealerships located in the U.S. and U.K, today announced that, subject to market conditions, it intends to offer for sale $625.0 million in...
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
COLUMBUS, Ohio, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bread Financial ® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S consumers, today announced the company’s participation in the Barclays 24 th Annual Global Financial Services Conference on Tuesday, September 15.
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612 ).